B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

88.22 +0.62 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 595,081
Open 87.68
Bid (Size) 83.99 (1)
Ask (Size) 89.00 (1)
Prev. Close 87.60
Today's Range 87.00 - 88.66
52wk Range 76.53 - 125.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
Exposures COVID-19

Performance

YTD
-21.47%
-21.47%
1 Month
+1.71%
+1.71%
3 Month
-10.66%
-10.66%
6 Month
-0.83%
-0.83%
1 Year
-29.47%
-29.47%

More News

Read More
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Unveiling 12 Analyst Insights On BioNTech
Via Benzinga
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
Via Benzinga
Exposures Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Via The Motley Fool
Why Pfizer Stock Slumped on Friday
Via The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
Via Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Via Benzinga
Exposures COVID-19
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Via Benzinga
Exposures COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Via Benzinga
Exposures COVID-19
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Via MarketBeat
Exposures COVID-19
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Via Investor's Business Daily
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.